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Abstract: For the treatment of glioma and other central nervous system diseases, one of the 
biggest challenges is that most therapeutic drugs cannot be delivered to the brain tumor tissue 
due to the blood–brain barrier (BBB). The goal of this study was to construct a nanodelivery 
vehicle system with capabilities to overcome the BBB for central nervous system administration. 
Doxorubicin as a model drug encapsulated in ganglioside GM1 micelles was able to achieve up 
to 9.33% loading efficiency and 97.05% encapsulation efficiency by orthogonal experimental 
design. The in vitro study demonstrated a slow and sustainable drug release in physiological 
conditions. In the cellular uptake studies, mixed micelles could effectively transport into both 
human umbilical vein endothelial cells and C6 cells. Furthermore, biodistribution imaging of 
mice showed that the DiR/GM1 mixed micelles were accumulated sustainably and distributed 
centrally in the brain. Experiments on zebrafish confirmed that drug-loaded GM1 micelles can 
overcome the BBB and enter the brain. Among all the treatment groups, the median survival 
time of C6-bearing rats after administering DOX/GM1 micelles was significantly prolonged. In 
conclusion, the ganglioside nanomicelles developed in this work can not only penetrate BBB 
effectively but also repair nerves and kill tumor cells at the same time.
Keywords: blood–brain barrier, GM1, nanovesicles, doxorubicin, glioma, zebrafish
Introduction
Previous studies have showed that over 80% of the intracranial tumors are malignant 
gliomas, which are essentially incurable and have a high rate of recurrence.1,2 
Glioblastoma is the most frequent and malignant brain tumor.3 Currently, the standard 
treatment for patients diagnosed with glioblastoma is temozolomide chemoradiotherapy 
postsurgery.4 Other chemotherapeutics have little effects because of the inherent resis-
tance of intracranial microenvironment against most cytotoxic drugs and the existence 
of blood–brain barrier (BBB)5 which consists of endothelial cells combined with tight 
intracellular junctions, pericytes, and astrocytes.6 The BBB, a diffusion barrier with 
selective permeability between blood and brain, can protect the normal function of the 
central nervous system (CNS). Meanwhile, approximately 100% of macromolecular 
drugs and over 98% of small-molecule compounds do not cross BBB and reach the 
brain tissue.5 Therefore, there is a growing need to develop safe and effective methods 
to deliver BBB-impermeable drugs into the brain.
Recently, there is a significant advance in the development of nanotechnology-
based pharmaceutical products.7 Nanomaterials, such as polymeric nanoparticles (NPs), 
liposomes, dendrimers, and micelles, are focused on overcoming BBB and enhancing 
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drug delivery.8 However, various potential risks, such as 
physicochemical properties and uncertain degradation pro-
cess of carrier materials, have the possibility of destroying 
the normal physiological functions of CNS. Consequently, it 
is crucial to choose appropriate carrier materials or construct 
nano-drug delivery systems.
Different from other types of tumors, glioma presents 
space-occupying lesions, which increase intracranial pressure 
and lead to secondary brain edema. The insertion of the tumor 
into brain tissue which leads to abnormal stress, as well as 
aggressive tumor growth would further trigger focal brain 
damage and compression of normal brain tissue.9 Malignant 
gliomas often extend well beyond tumor margin as defined by 
the surgeons. The local recurrence and neurological impair-
ment are frequent even after apparently complete removal of 
the tumor, which increases the risk of surgical resection of 
malignant gliomas.10 Furthermore, the nonselective toxicity 
of antineoplastic agents, clinical chemotherapy, and radio-
therapy is also known to be toxic to the nervous system.11,12 
Therefore, nerve repair in patients with glioblastoma should 
gain enough attention in clinical treatment.
Gangliosides consist of a hydrophilic sialic acid terminal 
sugar and a hydrophobic ceramide moiety, widely exist in 
neural tissue of vertebrates, and have been reported to modu-
late ion transport, neuronal differentiation, G protein-coupled 
receptors, immune system reactivities, and neuroprotective 
signaling.13,14 Monosialogangliosides GM1 play an impor-
tant role in regulating Ca2+ in the nucleus and maintaining 
neuronal homeostasis, which can affect neural function by 
modulating cell signaling, such as ERK1/2 phosphorylation 
and Na+/Ca2+ exchanger.15–17 Many studies have shown that 
GM1 gangliosides can play neuroprotective and neurorestor-
ative roles in neuronal injury, as well as induce neuritogenesis 
and promote cell differentiation.18–20 More importantly, GM1 
can overcome the BBB and treat neurological disease.21 
Exogenously administered GM1 have been widely used 
in clinical treatment of neurodegenerative diseases such as 
Parkinson and Alzheimer.17,22
Doxorubicin (DOX) is an anthracycline antibiotic widely 
used in treating various types of cancers. Unfortunately, DOX 
is not sufficiently effective due to its poor permeability of 
crossing BBB to achieve the therapeutic levels.23 Moreover, 
the fluorescent properties of DOX provide opportunities to 
track the molecules and DOX-loaded nanocarriers in cells 
or animals by using fluorescence-based techniques without 
any other fluorescence labels.24 Therefore in this study, DOX 
was used as a model drug.
In this work, we show that amphiphilic GM1 can spon-
taneously self-assemble into micelles that could be used to 
solubilize hydrophobic drugs (DOX) in aqueous solution. 
The primary goal of our study is to evaluate the ability 
of GM1 micelles to overcome BBB and establish a novel 
strategy for targeting malignant brain tumors, for repairing 
nerves and killing tumor cells simultaneously.
Materials and methods
Materials
DOX was purchased from meilunepharma (Dalian, People’s 
Republic of China). Purified monosialogangliosides GM1 
were kindly provided by Huan Rui (Chongqing, People’s 
Republic of China). DiR iodide (1,1′-dioctadecyl-3,3,3′,3′-
tetramethyl indotricarbocyanine iodide) (DiR) fluorescent 
probes were purchased from KeyGen Biotech (Nanjin, 
People’s Republic of China). Dulbecco’s Modified Eagle’s 
Medium (DMEM) and Medium 199 were purchased from 
HyClone (Logan, UT, USA). Trypsin (0.25%) was pur-
chased from Thermo Fisher Scientific (Waltham, MA, 
USA). 4′,6-Diamidino-2-phenylindole (DAPI) was sup-
plied by Beyotime Biotechnology (Shanghai, People’s 
Republic of China). All other solvents used were of ana-
lytical grade.
Preparation and characterization of 
DOX/gM1 micelles
A method was developed and validated for preparing mixed 
micelles of GM1 and DOX according to Leonhard et al.25 
A stock solution of purified monosialogangliosides GM1 was 
prepared in triple-distilled water 24 h prior to use. The solu-
tion was maintained at 4°C for 24 h, and then centrifuged at 
10,000× g for 15 min, and the supernatant was filtered 
through 0.22-µm filter.
A stock solution of DOX was prepared in dimethyl sul-
foxide (DMSO). Then, the DOX solution was slowly added 
to GM1 micelles solution.
The DOX-loaded GM1 micelles were incubated at 4°C 
for 24 h and dialyzed for 24 h to remove all the DMSO.
Optimizing preparation of DOX/gM1 
micelles
The concentration and molar ratio of both drug and carrier 
are considered as key factors in the preparation of micelles. 
Orthogonal experimental design (OED) method was used for 
constructing the best combination levels for different factors 
(Table 1). GM1 concentration (A), DOX concentration (B), 
and GM1/DOX molar ratio (C: A × B) varied at three different 
levels when preparing micelles. The drug-loading efficiency 
of these nine combinations was evaluated by software SPSS 
to identify the best combination.
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size and surface charge determination
Micelles size and zeta potential were measured by dynamic 
light scattering (DLS) using Zetasizer (Nano ZS90; 
Malvern Instruments, Malvern, UK) at 25°C and refractive 
index of 1.57.
electron microscopy
The morphology of the micelles was characterized through 
a JEM 1200EX transmission electron microscope. The 
samples were prepared by loading 30 µL on the carbon-
coated copper grid, which was allowed to stand for 5 min, 
and the redundant solution was absorbed with filter paper. 
The copper grid was dyed with a drop of uranyl acetate for 
90 s and then dehydrated.
DOX loading and encapsulation
Ultraviolet spectroscopy was followed to evaluate the drug 
loading of DOX/GM1 micelles on a UV spectrophotometer 
(T6-New Century; Purkinje General Instrument Co., Ltd. 
Beijing, People’s Republic of China). Lyophilized DOX-
loaded micelles were dissolved in N,N-dimethylformamide 
(DMF) and analyzed by measuring the absorbance, wherein 
calibration curve of DOX/DMF was established at 480 nm 
with enhanced concentrations of DOX in the range of 10–45 
mg⋅mL−1. The drug loading and encapsulation efficiency were 
calculated as follows:
 
= Drug contents of  mixed micellesLoading efficiency %
The weight of  mixed micelles  
 
= ⋅
Encapsulation Drug content of  mixed micelles
 
efficiency % The quantity of  reagent  
DOX release in vitro
We assessed the drug release profile of DOX/GM1 in 
phosphate-buffered saline (PBS, 0.01 M, pH 7.4) through a 
dialysis bag of molar weight cutoff (MWCO) =2,000. The 
calibration curve of DOX in PBS buffer was established at 
480 nm, and a linear relationship was obtained with a correla-
tion coefficient of 0.9996. Lyophilized micelles (20 mg) were 
dissolved in 2 mL PBS, and the solution was then transferred 
to dialysis bags which were immersed in PBS buffer. The 
dissolution medium (20 mL) was placed in an incubator at 
37°C and 100 rpm throughout the drug release experiment. 
At selected time intervals, 3-mL sample was collected with 
the replacement of the same volume of fresh PBS solution. 
The release amount of DOX was evaluated using ultraviolet 
(UV) detection.
cell culture
Human umbilical vein endothelial cells (HUVECs) (China 
Center for Type Culture Collection) were cultured in the 
endothelial cell culture medium (high-glucose DMEM, 10% 
FBS, 100 U/mL penicillin, 100 µg⋅mL−1 streptomycin) and 
digested by 0.25% trypsin for about 30 s.
C6 glioma cells (Kunming Cell Bank, CAS, Kunming, 
People’s Republic of China) were grown in RPMI 1640 
medium supplemented with 2.5% (v/v) FBS, 10% (v/v) horse 
serum, 100 U/mL penicillin, and 100 µg⋅mL−1 streptomycin, 
and digested by 0.05% trypsin (diluted with PBS solution) 
for about 20 s.
Cells were maintained in a 5% CO
2
 incubator at 37°C.
In vitro cellular uptake
Cellular uptake of micelles was studied by confocal laser 
scanning microscopy (CLSM, Leica TCS SP5). HUVECs 
and C6 cells were seeded in laser confocal petri dishes at a 
density of 2×105 cells per dish and grown for 24 h with 5% CO
2
 
at 37°C. The cells were incubated with DOX (10 µg⋅mL−1) 
solution and DOX/GM1 micelles for 0.5, 2, and 4, respec-
tively. The cells were washed with PBS (pH 7.4) for three 
times and fixed with 4% paraformaldehyde for 15 min. 
The liquid was removed and washed with PBS twice. 
DAPI was added to stain nuclei. Then, cells were observed 
by CLSM.
In vivo distribution behavior of 
Dir-loaded micelles
The Institutional Animal Care and Use Committee of 
Chongqing University approved all animal (including mice 
and zebrafish) experiments, procedures, and protocols, and 
all animals were cared for in accordance with the guide for 
the Care and Use of Laboratory Animals.
The male Kunming (KM) mice, with body weights of 
20–23 g, were procured from Laboratory Animal Center, 
Third Military Medicinal University (Chongqing, People’s 
Republic of China). The preparation of DiR-loaded micelles 
Table 1 Factors and levels of the preparation of DOX/gM1 
micelles
Levels Factors
A: GM1 
concentration 
(mg⋅mL−1)
B: DOX 
concentration 
(mg⋅mL−1)
C: GM1/DOX 
(mol/mol)
l1 100 6 50/1
l2 50 3 25/1
l3 25 1.5 5/1
Abbreviation: DOX, doxorubicin.
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is consistent with the method of preparation of mixed micelles 
of GM1 and DOX. Mice were starved for 12 h before receiv-
ing a single dose (25 µg/mouse) of the DiR and DiR/GM1 
micelles intravenously. Mice were monitored by In-Vivo FX 
PRO for small-animal imaging after anesthesia.
Transgenic fluorescent zebrafish for 
micelles to overcome BBB
Transgenic fluorescent zebrafish (flk1: GFP) was incubated 
at 28°C according to standard zebrafish care and procedures. 
Four days postfertilization (dpf), zebrafish embryos were 
anesthetized with tracaine (4 g⋅L−1). Intracardiac injection 
with 5-nL DOX or DOX/GM1 using a PV 820 Pneumatic 
PicoPump was followed by fixing with 1.2% low-melting 
point agarose. Finally, the embryos were imaged at different 
time points (20 min, 60 min) using CLSM.
Therapeutic efficacy in tumor-bearing 
rats
Male Wistar rats weighing 300±10 g were purchased 
from Chongqing Academy of Chinese Materia Medica 
(Chongqing, People’s Republic of China). All animals were 
kept under standard conditions with free access to food and 
water. The cranium was exposed after animals were deeply 
anesthetized with 10% chloralic hydras. Approximate 5×105 
C6 glioma cells/15 µL in 1640 medium were stereotaxically 
implanted into the right forebrain of each rat at the specific 
site: 1.0 mm anterior and 3.0 mm lateral from the bregma 
at a depth of 4.5 mm from the brain surface.26 Eight days 
after tumor inoculation, rats were randomly divided into five 
groups (n=5). The DOX solution, GM1 solution, DOX + 
GM1 and DOX/GM1 micelles, and physiological saline 
(blank control group) were injected intravenously via tail 
vein with DOX concentration of 3 mg/kg per dose, and all 
the solutions except DOX and saline had the same GM1 
concentration. The drugs were given every 3 days with a total 
of three doses per rat. On day 20, one rat from each group 
was monitored by magnetic resonance imaging (MRI) for 
measuring the tumor size, and the animals were sacrificed 
with brain tissue dissected for hematoxylin and eosin (H&E) 
staining. The survival outcome and neurological examination 
were calculated daily after inoculation of C6 tumor cells. 
Kaplan–Meier survival curves were plotted for each group.
Results and discussion
Preparation and characterization of 
DOX/gM1 micelles
Gangliosides are sialic acid-containing glycosphingolipids 
and generated mostly in the nervous system.27,28 In aqueous 
solution, most gangliosides form micelles with very low critical 
micelle concentration values, of the order of 10−10–10−8 M.29,30 
These properties suggest that a novel GM1 micelles system 
can be constructed for hydrophobic or amphipathic active 
pharmaceuticals. Both molar ratio of GM1/DOX and their 
concentrations could play important roles in the formation 
of DOX-loaded GM1 micelles. The optimum micelles (GM1 
concentration: 50 mg⋅mL−1, DOX concentration: 3 mg⋅mL−1, 
GM1/DOX: 5/1) were obtained through the OED method.
The DOX/GM1 micelles were prepared using dialysis 
method. The DLS analysis revealed that the DOX-loaded 
GM1 aggregated to particles with an average size of 226 nm 
(Figure 1A). The zeta potential measurement showed that 
surface was negatively charged with −45.7 mV (Figure 1B). 
The high magnitude of zeta potential can prevent particle 
aggregation during storage.31 Compared to cationic NPs, 
anionic NPs cause less disruption of plasma-membrane 
integrity, weaker damage of lysosomal and mitochondrial 
membrane,32 and less neuron toxic response.33 As shown 
in transmission electron microscopy (TEM) images, the 
DOX-loaded GM1 micelles were spherical with an average 
diameter of 5–21 nm, but the particles size was mainly 
between 8 and 14 nm for the mixed micelles (Figure 1C). 
However, the particle size measured by TEM was smaller 
than that measured by DLS. This is mainly because DLS 
measures aggregate size in the hydrated state, while the 
particle is dehydrated when measured by TEM.34
Due to its amphiphilicity, GM1 can spontaneously self-
assemble into micelles which enables solubilization of hydro-
phobic DOX in an aqueous environment. DOX was loaded 
onto GM1 micelles by dialysis method. The concentration 
of DOX/GM1 micelle was 9.33%, and the micelle showed 
high encapsulation efficiency (97.05%).
The in vitro drug release experiments were carried 
out for DOX/GM1 micelles with an NP concentration of 
10 mg⋅mL−1, and DOX release profiles were studied under 
physiological condition (pH 7.4, 37°C). The results demon-
strated that the release of DOX from micelles was slow and 
sustainable without a burst release effect (Figure 1D). The 
cumulative release of DOX was limited to 66.53% over a 
period up to 16 days. The release rate of DOX decreased 
gradually. It was found that 45.75% of drug was released 
within the first 51 h. The releasing quantity after 51 h was 
about 20%. It is generally recognized that the physical pro-
cess of encapsulation of hydrophobic drugs in GM1 micelle 
is mainly driven by the hydrophobic interaction between drug 
and hydrophobic segments of ganglioside.35 The interactions 
between hydrophobic portion and DOX, and slow degrada-
tion of ganglioside may be responsible for the controlled drug 
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release. As stated above, DOX-loaded micelle seems to be 
a promising and viable technology platform for controlled 
drug delivery.
In vitro cellular uptake study
The cellular uptake efficiency of micelles was studied in 
HUVECs and C6 cells through CLSM with DAPI staining.36 
As shown in Figure 2, HUVECs and C6 cells treatment with 
free DOX displayed DOX fluorescence in cytoplasm after 
0.5 h, and the fluorescence was distributed in nucleus within a 
short period of 2–4 h. In comparison, the red fluorescence was 
observed after 0.5 h and enhanced in nuclei after incubation 
with DOX/GM1. There was no significant difference in fluo-
rescence intensity between 2-h and 4-h incubation. Scanning 
electron microscopy results indicated that free DOX entered 
the cell and gathered at nucleus but was excreted with reduced 
nuclear fluorescence. Removal of DOX from the nucleus 
is likely mediated by P-glycoprotein located in the plasma 
membrane, Golgi apparatus, and nucleus, which serves as an 
ATP-coupled active drug efflux pump of hydrophobic com-
pounds conferring multidrug resistance (MDR) to HUVECs 
and C6 cells.37 However, it is a notable finding that in this 
study, the efflux mechanism failed to pump out DOX/GM1 
micelles. The use of targeted micelles for chemotherapeutic 
delivery may conceivably circumvent the MDR drug efflux 
mechanism, which leads to resistance, albeit the mechanism 
is unclear.38 In recent years, numerous carrier-mediated 
transporters or receptors have demonstrated that BBB has 
the capability to control the uptake of chemotherapeutics 
into the brain. Drug delivery systems (NPs, micelles, etc.) 
have been used to strengthen the ability of overcoming the 
BBB via the binding effect between specific ligands equipped 
on the surface of the delivery system and the specific endog-
enous transporters localized on the BBB.39 The uptake of 
DOX/GM1 micelles may be attributed to that polymersome 
nanocarriers functionalized with GM1-targeting peptides 
could bind BBB receptors and get transferred in the brain 
endothelial cells in vitro.40
In vivo distribution behavior of 
Dir-loaded micelles
The In-Vivo FX PRO animal imaging system was used for 
investigating the in vivo biodistribution and brain-targeting 
efficiency of DiR/GM1 micelles. As shown in Figure 3, 
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Figure 1 size distribution (A) and surface potential (B) were determined by dynamic light scattering. Transmission electron microscopy (C) and frequency histograms (D) 
of DOX-loaded GM1 micelles. Scale bar: 50 nm. Drug release profile of DOX from GM1 micelles at pH 7.4 and 37°c in PBs buffer (E and F).
Abbreviations: DOX, doxorubicin; PBs, phosphate-buffered saline.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
10
7 
on
 2
0-
Ju
l-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4884
Zou et al
fluorescence signal of control group was observed in the 
liver after free DOX injection, due to the cellular uptake by 
phagocytic cells in reticuloendothelial system.41 Moreover, 
in DiR-loaded GM1 micelles, fluorescence signal from 
DiR/DOX micelles was observed in the mice brain during 
the whole monitoring period. The fluorescence signal inten-
sity was strong until 9 h and became weak after 24 h. As a 
result of the physical formation process, GM1 micelles may 
still maintain the same specific groups with GM1 molecule, 
which contributes to transmembrane transportation. As 
demonstrated in a previous study,25 when interacting with 
blood, the GM1/Ptx mixed micelles form ternary complexes 
with albumin, and albumin binding to the gp60 receptor of 
endothelial cells could promote transcytosis. In addition, 
GM1 ganglioside facilitates long circulating time in vivo by 
suppressing phagocytosis.42
Transgenic fluorescent zebrafish for 
micelles to overcome BBB
To study the ability of DOX-loaded GM1 micelle to cross 
the BBB in vivo, DOX/GM1 micelle and DOX solution were 
injected into the circulation of zebrafish (4 dpf) through the 
heart, and the in vivo imaging of the brain was monitored. 
As expected, mixed micelles extravasated extensively from 
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Figure 2 Kinetics of cellular uptake of free DOX and DOX/gM1 incubated with hUVecs (A, scale bars: 50 µm) and c6 cells (B, scale bars: 25 µm), respectively.
Abbreviations: DaPI, 4′,6-diamidino-2-phenylindole; DOX, doxorubicin; hUVecs, human umbilical vein endothelial cells.
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vessels (green), as evidenced by fluorescence of DOX (red) 
within the brain parenchyma (Figure 4, arrows). In contrast, 
DOX was not observed in the brain but confined to the blood 
vessels. The results indicated that GM1 micelles could effec-
tively deliver the drugs into brain tissue by overcoming the 
BBB, although astroglial structures in zebrafish brain differ 
from mammalian astrocytes.43 Due to rapid growth, large 
number of offspring, and a similar BBB function to human,44 
zebrafish is suitable for the study of BBB and drug delivery. 
Only 3 days after fertilization, embryonic zebrafish shows the 
development of a functional endothelial-based BBB that has 
similar properties to mammals,45 and it is used in many studies 
focusing on overcoming BBB.46,47 Furthermore, the BBB-
crossing ability of DOX/GM1 micelles could be observed 
intuitively in the transgenic fluorescent zebrafish (flk1: GFP) 
due to its vascular labeling. No studies have suggested that 
GM1 micelle is a viable carrier for delivering drugs across the 
BBB. However, our results demonstrated that GM1 micelles 
facilitated DOX delivery to the brain. In the experiment with 
zebrafish, no fluorescence was detected in the group injected 
with DOX, while there was significant penetration of the 
BBB as demonstrated by the red fluorescence in DOX/GM1 
micelles. Therefore, the results of biodistribution assays and 
BBB penetration in vivo indicated the feasibility of using 
GM1 ganglioside micelle as a brain carrier.
Therapeutic efficacy in tumor-bearing 
rats
To reveal the potential antitumor and nerve injury-repairing 
functions of DOX/GM1 in glioma therapy, brain tumor-
bearing rat models were established and treated with different 
GM1 and DOX formulations via tail intravenous injection.
Twenty days after C6 implantation, one rat in each group 
was randomly selected to monitor the tumor growth through 
MRI (MAGNETOM Avanto 1.5T). T
2
 weighted images are 
shown in Figure 5A (MRI); the obvious tumor was found 
in all groups. The size of the tumor in control group was up 
to 0.9×0.8 cm, whereas the size was 0.64×0.58, 0.68×0.61, 
0.66×0.43, and 0.4×0.4 cm in GM1, DOX, GM1 + DOX, and 
DOX/GM1 groups, respectively. The smallest tumor size in 
DOX/GM1 group demonstrated that it has the best antitumor 
capacity compared to other treatment groups.
The histopathological changes in glioma of all treatment 
groups were examined 20 days after tumor implantation. 
K
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Figure 3 In vivo fluorescence imaging of Kunming mice at different time points after administration with free DiR (control) and DiR/GM1 micelle.
Abbreviation: Dir, 1,1′-dioctadecyl-3,3,3′,3′-tetramethyl indotricarbocyanine iodide.
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The H&E staining (Figure 5B) was performed to evaluate 
tumor necrosis.48 Negligible necrosis of tumor was observed 
in the group treated with saline, while the group treated with 
GM1 + DOX exhibited obvious necrosis which was more 
significant than GM1 or DOX group. Furthermore, much 
more extensive necrosis phenomenon was detected in glioma 
tissues treated with DOX/GM1 micelles. These H&E staining 
results also indicated the therapeutic effects of these treatment 
groups, which were consistent with results of MRI.
Moreover, to assess the antitumor effects of different 
treatment groups, the survival time of tumor-bearing rats 
is presented as a Kaplan–Meier plot in Figure 5C. The sur-
vival time of rats in the saline control group was 17–23 days 
(median survival: 19.6 days). The median survival time was 
21.6, 23.4, 24.8, and 26.8 days for GM1, DOX, DOX + GM1, 
and DOX/GM1 groups, respectively. Animals treated with 
GM1 solution had a little difference in survival time com-
pared to saline group; the possible reason was that GM1 could 
repair nerve injuries caused by tumor growth. Though DOX 
has poor targeting efficiency, DOX solution could prolong 
the median survival time, which is mainly ascribed to its 
broad-spectrum anticancer activity.49 DOX + GM1 solution 
combined the advantages of antitumor effect and neuron 
repair, resulting in longer median survival time. Because of 
BBB penetration, the DOX/GM1 group showed prolonged 
survival among all the treatment groups.
In our studies, the neurological function of rats was 
recorded after implantation of C6 tumor cells to evaluate 
the neuroprotective and neurorestorative roles of GM1 in 
neuronal injury. The assessment of neurological score was 
in accordance with the Garcia scale, including spontaneous 
activity, symmetry in the movement of four limbs, forepaw 
outstretching, climbing, body proprioception, and vibrissae 
touch, which is scored on a scale from 3 to 18.50 As shown in 
Figure 5D, the neuroscore of rats in GM1, GM1 + DOX, and 
GM1/DOX groups remained as at least 10 points, while the 
conditions of the rats treated with saline and DOX solution 
were not satisfactory, which showed significant neurological 
impairment before the rats’ death. The results were consistent 
with previous studies which showed GM1 ganglioside pro-
motes functional recovery of the damaged nerves, and also 
confirmed GM1 micelle is capable of passing the BBB.
In summary, the therapeutic effect of DOX/GM1 micelles 
was more powerful than normal saline, free DOX, free GM1, 
PLQDIWHULQMHFWLRQ
'2;
'2;
*0

PLQDIWHULQMHFWLRQ
Figure 4 Intracardiac injection of DOX/GM1 micelle and DOX into transgenic (flk1: GFP) zebrafish. The arrowhead indicates micelles crossing out of vessels (green). DOX 
retained within vessels without the gM1 micelle is shown in red. scale bars: 75 µm.
Abbreviation: DOX, doxorubicin.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
10
7 
on
 2
0-
Ju
l-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4887
antitumor activity and nerve repair by DOX/gM1 micelles
%
& '
$ &RQWUROVDOLQH
05
,
+	(
*0VROXWLRQ '2;VROXWLRQ '2;*0VROXWLRQ '2;*0PLFHOOH
7LPHGD\V






      
6XU
YLYD
O

6DOLQH)UHH*0)UHH'2;'2;*0'2;*0 




       
1HX
URV
FRU
H
7LPHGD\V
6DOLQH)UHH*0)UHH'2;'2;*0'2;*0
Figure 5 MrI images (A), h&e staining (B, ×100), Kaplan–Meier plot (C), and neuroscore (D) of tumor-bearing rats after treatment with saline, free gM1 solution, free 
DOX solution, DOX + gM1 solution, and DOX/gM1 micelle, respectively. White arrows in MrI images indicate the tumor, and yellow arrows in h&e staining indicate 
tumor necrosis.
Abbreviations: DOX, doxorubicin; h&e, hematoxylin and eosin.
and DOX + GM1, as demonstrated by prolonged survival 
time, reduced tumor size, and extensive tumor necrosis by 
histological examination. More importantly, our data con-
firmed that GM1 formulations could improve nerve functions 
of the animals with brain tumors.
Conclusion
In this study, ganglioside GM1 micelles were designed and 
synthesized. The anticancer drug DOX was spontaneously 
encapsulated into the nanomicelles. In aqueous solution, the 
mixed micelles self-assembled into spherical and uniform 
NPs which exhibited slow drug release. In addition, the 
DOX/GM1 micelles showed promising BBB-overcoming 
and brain-targeting efficacy in vitro and in vivo. As stated 
above, GM1 micelles, a novel nanodelivery system, can 
not only penetrate BBB effectively but also repair nerves 
at the same time. Thus, the drug-loaded GM1 micelles with 
multiple functions have great potential for drug delivery to 
treat intracranial diseases such as brain tumor and neurode-
generative diseases.
Acknowledgments
This work was supported by the National Key Basic 
Research Project (973) (2014CB541600), the Fundamental 
Research Funds for the Central Universities (2015CDJZR), 
graduate scientific research and innovation foundation 
of Chongqing, People’s Republic of China (Grant No 
CYS16015), and National Natural Science Foundation of 
China (31200713). In particular, the authors would like 
to acknowledge Mr Fei Fang (College of Bioengineering, 
Chongqing University) for his help in collecting data on 
BBB-overcoming potential of micelles using transgenic 
fluorescent zebrafish.
Disclosure
The authors report no conflicts of interest in this work.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
10
7 
on
 2
0-
Ju
l-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4888
Zou et al
References
 1. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecu-
lar pathology to targeted treatment. Annu Rev Pathol. 2014;9:1–25.
 2. Chen J, McKay RM, Parada LF. Malignant glioma: lessons from 
genomics, mouse models, and stem cells. Cell. 2012;149(1):36–47.
 3. Silva AC, Oliveira TR, Mamani JB, et al. Application of hyperthermia 
induced by superparamagnetic iron oxide nanoparticles in glioma treat-
ment. Int J Nanomedicine. 2011;6:591–603.
 4. Stupp R, Hegi ME, Gorlia T, et al; European Organisation for 
Research and Treatment of Cancer (EORTC); Canadian Brain Tumor 
Consortium; CENTRIC study team. Cilengitide combined with stan-
dard treatment for patients with newly diagnosed glioblastoma with 
methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): 
a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 
2014;15(10):1100–1108.
 5. Pardridge WM. Blood–brain barrier delivery. Drug Discov Today. 2007; 
12(1–2):54–61.
 6. Li Y, He H, Jia X, Lu WL, Lou J, Wei Y. A dual-targeting nano-
carrier based on poly (amidoamine) dendrimers conjugated with 
transferrin and tamoxifen for treating brain gliomas. Biomaterials. 
2012;33(15):3899–3908.
 7. Caraglia M, De Rosa G, Salzano G, et al. Nanotech revolution for the 
anti-cancer drug delivery through blood-brain-barrier. Curr Cancer 
Drug Targets. 2012;12(3):186–196.
 8. De Rosa G, Salzano G, Caraglia M, Abbruzzese A. Nanotechnologies: 
a strategy to overcome blood-brain barrier. Curr Drug Metab. 2012; 
13(1):61–69.
 9. Onishi M, Ichikawa T, Kurozumi K, Date I. Angiogenesis and invasion 
in glioma. Brain Tumor Pathol. 2011;28(1):13–24.
 10. Parvez T. Present trend in the primary treatment of aggressive malignant 
glioma: glioblastoma multiforme. Technol Cancer Res Treat. 2008; 
7(3):241–248.
 11. Chen XF, Wang R, Yin YM, et al. The effect of monosialotetrahex
osylganglioside (GM1) in prevention of oxaliplatin induced neuro-
toxicity: a retrospective study. Biomed Pharmacother. 2012;66(4): 
279–284.
 12. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions 
for preventing neuropathy caused by cisplatin and related compounds. 
Cochrane Database Syst Rev. 2014;(3):CD005228.
 13. Allende ML, Proia RL. Lubricating cell signaling pathways with gan-
gliosides. Curr Opin Struct Biol. 2002;12(5):587–592.
 14. Ledeen RW, Wu G. The multi-tasked life of GM1 ganglioside, a true 
factotum of nature. Trends Biochem Sci. 2015;40(7):407–418.
 15. Ledeen R, Wu G. New findings on nuclear gangliosides: overview on 
metabolism and function. J Neurochem. 2011;116(5):714–720.
 16. Schengrund CL. Gangliosides: glycosphingolipids essential for normal 
neural development and function. Trends Biochem Sci. 2015;40(7): 
397–406.
 17. Wu G, Lu ZH, Kulkarni N, Amin R, Ledeen RW. Mice lacking major 
brain gangliosides develop parkinsonism. Neurochem Res. 2011;36(9): 
1706–1714.
 18. Ariga T, McDonald MP, Yu RK. Role of ganglioside metabolism in the 
pathogenesis of Alzheimer’s disease – a review. J Lipid Res. 2008;49(6): 
1157–1175.
 19. Mocchetti I. Exogenous gangliosides, neuronal plasticity and repair, and 
the neurotrophins. Cell Mol Life Sci. 2005;62(19–20):2283–2294.
 20. Skaper SD, Leon A, Toffano G. Ganglioside function in the develop-
ment and repair of the nervous system. From basic science to clinical 
application. Mol Neurobiol. 1989;3(3):173–199.
 21. Li S, Xiao N, Zhang X, et al. Effects of exogenous ganglioside-1 on 
learning and memory in a neonatal rat model of hypoxia-ischemia brain 
injury. Neural Regen Res. 2008;3(9):1004–1009.
 22. Williams TL, Serpell LC. Membrane and surface interactions of 
Alzheimer’s Aβ peptide – insights into the mechanism of cytotoxicity. 
FEBS J. 2011;278(20):3905–3917.
 23. Hanušová V, Tomšík P, Kriesfalusyová L, Pakostová A, Boušová I, 
Skáalová L. In vivo effect of oracin on doxorubicin reduction, biodis-
tribution and efficacy in Ehrlich tumor bearing mice. Pharmacol Rep. 
2013;65(2):445–452.
 24. Blazkova I, Viet Nguyen H, Kominkova M, et al. Fullerene as a trans-
porter for doxorubicin investigated by analytical methods and in vivo 
imaging. Electrophoresis. 2014;35(7):1040–1049.
 25. Leonhard V, Alasino RV, Bianco ID, Garro AG, Heredia V, Beltramo DM. 
Self-assembled micelles of monosialogangliosides as nanodelivery 
vehicles for taxanes. J Control Release. 2012;162(3):619–627.
 26. Xu X, Li J, Han S, et al. A novel doxorubicin loaded folic acid conju-
gated PAMAM modified with borneol, a nature dual-functional product 
of reducing PAMAM toxicity and boosting BBB penetration. Eur J 
Pharm Sci. 2016;88:178–190.
 27. Bremer EG, Hakomori S, Bowen-Pope DF, Raines E, Ross R. Ganglioside-
mediated modulation of cell growth, growth factor binding, and 
receptor phosphorylation. J Biol Chem. 1984;259(11):6818–6825.
 28. Yu RK, Tsai YT, Ariga T, Yanagisawa M. Structures, biosynthesis, 
and functions of gangliosides – an overview. J Oleo Sci. 2011;60(10): 
537–544.
 29. Formisano S, Johnson ML, Lee G, Aloj SM, Edelhoch H. Critical 
micelle concentrations of gangliosides. Biochemistry. 1979;18(6): 
1119–1124.
 30. Corti M, Cantù L, Favero ED. Peculiarities in the aggregative behaviour 
of gangliosides, glucosidic surfactants of biological origin. IL Nuovo 
Cimento D. 1994;16(9):1391–1400.
 31. Pan K, Chen H, Davidson PM, Zhong Q. Thymol nanoencapsulated 
by sodium caseinate: physical and antilisterial properties. J Agric Food 
Chem. 2014;62(7):1649–1657.
 32. Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of 
medical nanoparticles. Int J Nanomedicine. 2012;7(11):5577–5591.
 33. Beddoes CM, Case CP, Briscoe WH. Understanding nanoparticle cel-
lular entry: a physicochemical perspective. Adv Colloid Interface Sci. 
2015;218:48–68.
 34. She W, Luo K, Zhang C, et al. The potential of self-assembled, pH-
responsive nanoparticles of mPEGylated peptide dendron–doxorubicin 
conjugates for cancer therapy. Biomaterials. 2013;34(5):1613–1623.
 35. Ma C, Pan P, Shan G, Bao Y, Fujita M, Maeda M. Core-shell struc-
ture, biodegradation, and drug release behavior of poly(lactic acid)/
poly(ethylene glycol) block copolymer micelles tuned by macromo-
lecular stereostructure. Langmuir. 2015;31(4):1527–1536.
 36. Neuhaus W, Gaiser F, Mahringer A, Franz J, Riethmüller C, Förster C. 
The pivotal role of astrocytes in an in vitro stroke model of the blood-
brain barrier. Front Cell Neurosci. 2014;8(6):352.
 37. Roepe PD. Analysis of the steady-state and initial rate of doxorubicin 
efflux from a series of multidrug-resistant cells expressing different 
levels of P-glycoprotein. Biochemistry. 1993;31(50):12555–12564.
 38. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, 
Gabizon A. Nuclear delivery of doxorubicin via folate-targeted lipo-
somes with bypass of multidrug-resistance efflux pump. Clin Cancer Res. 
2000;6(5):1949–1957.
 39. Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes 
improve the therapeutic efficacy of brain glioma in animals. J Control 
Release. 2009;141(2):183–192.
 40. Stojanov K, Georgieva JV, Brinkhuis RP, et al. In vivo biodistribution 
of prion- and GM1-targeted polymersomes following intravenous 
administration in mice. Mol Pharm. 2012;9(6):1620–1627.
 41. Liang DS, Su HT, Liu YJ, Wang AT, Qi XR. Tumor-specific pen-
etrating peptides-functionalized hyaluronic acid-D-α-tocopheryl suc-
cinate based nanoparticles for multi-task delivery to invasive cancers. 
Biomaterials. 2015;71:11–23.
 42. Adibhatla RM, Hatcher JF, Tureyen K. CDP-choline liposomes provide 
significant reduction in infarction over free CDP-choline in stroke. 
Brain Res. 2005;1058(1–2):193–197.
 43. Grupp L, Wolburg H, Mack AF. Astroglial structures in the zebrafish 
brain. J Comp Neurol. 2010;518(21):4277–4287.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
10
7 
on
 2
0-
Ju
l-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
 MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
4889
antitumor activity and nerve repair by DOX/gM1 micelles
 44. Umans RA, Taylor MR. Zebrafish as a model to study drug transporters at 
the blood-brain barrier. Clin Pharmacol Ther. 2012;92(5):567–570.
 45. Jeong JY, Kwon HB, Ahn JC, et al. Functional and developmental 
analysis of the blood-brain barrier in zebrafish. Brain Res Bull. 2008; 
75(5):619–628.
 46. Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs 
across the blood-brain barrier for brain cancer therapy in Danio rerio. 
Pharm Res. 2015;32(6):2003–2014.
 47. Guemez-Gamboa A, Nguyen LN, Yang H, et al. Inactivating mutations 
in MFSD2A, required for omega-3 fatty acid transport in brain, cause 
a lethal microcephaly syndrome. Nat Genet. 2015;47(7):809–813.
 48. Zhang B, Sun X, Mei H, et al. LDLR-mediated peptide-22-conjugated 
nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 
2013;34(36):9171–9182.
 49. Ruan S, Yuan M, Zhang L, et al. Tumor microenvironment sensitive 
doxorubicin delivery and release to glioma using angiopep-2 decorated 
gold nanoparticles. Biomaterials. 2015;37:425–435.
 50. Desland FA, Afzal A, Warraich Z, Mocco J. Manual versus automated 
rodent behavioral assessment: comparing efficacy and ease of Bederson 
and Garcia neurological deficit scores to an open field video-tracking 
system. J Cent Nerv Syst Dis. 2014;6:7–14.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
10
7 
on
 2
0-
Ju
l-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
